Online inquiry

IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8538MR)

This product GTTS-WQ8538MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8538MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9753MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ2042MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ8113MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ8142MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ15351MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ6282MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ8024MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ13856MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW